Compare Stocks → Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars (From GoldenCrest Metals) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:EIGRNASDAQ:FENCNASDAQ:GNFTNASDAQ:JNCENASDAQ:PSTI Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEIGREiger BioPharmaceuticals$4.85$1.10▼$43.35$2.55M1.83103,866 shs137,800 shsFENCFennec Pharmaceuticals$9.30+0.6%$10.05$6.30▼$11.92$252.03M0.38112,785 shs4,026 shsGNFTGenfit$3.61+4.9%$3.60$2.89▼$4.75$179.89M1.0814,873 shs722 shsJNCEJounce Therapeutics$1.88-2.6%$1.89$0.58▼$5.87$98.94M0.752.46 million shs11.60 million shsPSTIPluristem Therapeutics$1.24$0.95▼$3.45$32.35M1.91715,259 shs2,128 shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEIGREiger BioPharmaceuticals0.00%0.00%-70.05%-71.77%-94.36%FENCFennec Pharmaceuticals-1.49%-9.94%-14.44%-8.33%+15.36%GNFTGenfit0.00%-5.51%-6.79%-13.38%-8.04%JNCEJounce Therapeutics0.00%0.00%0.00%0.00%-1.05%PSTIPluristem Therapeutics0.00%0.00%0.00%0.00%0.00%Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars (Ad)Big Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.Learn More NowMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEIGREiger BioPharmaceuticals3.8759 of 5 stars3.55.00.04.20.61.70.0FENCFennec Pharmaceuticals2.4133 of 5 stars3.50.00.00.02.32.51.9GNFTGenfit0.8313 of 5 stars3.53.00.00.00.60.00.0JNCEJounce TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APSTIPluristem TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEIGREiger BioPharmaceuticals3.00Buy$120.00∞ UpsideFENCFennec Pharmaceuticals3.00Buy$17.3386.38% UpsideGNFTGenfit3.00Buy$11.00204.71% UpsideJNCEJounce TherapeuticsN/AN/AN/AN/APSTIPluristem TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest PSTI, JNCE, FENC, EIGR, and GNFT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/5/2024GNFTGenfitHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.004/4/2024FENCFennec PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.003/18/2024FENCFennec PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.003/18/2024FENCFennec PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$16.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEIGREiger BioPharmaceuticals$15.77M0.00N/AN/A$37.68 per share0.00FENCFennec Pharmaceuticals$21.25M11.86N/AN/A($0.43) per share-21.63GNFTGenfit$41.31M4.35N/AN/A$1.48 per share2.44JNCEJounce Therapeutics$82M1.21N/AN/A$3.54 per share0.53PSTIPluristem Therapeutics$20K0.00N/AN/A$1.80 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEIGREiger BioPharmaceuticals-$96.78M-$59.16N/AN/AN/A-590.80%-332.49%-99.77%5/9/2024 (Estimated)FENCFennec Pharmaceuticals-$16.05M-$0.61N/A13.29N/A-75.50%N/A-73.64%5/9/2024 (Estimated)GNFTGenfit-$31.27MN/A0.00N/AN/AN/AN/AN/A7/4/2024 (Estimated)JNCEJounce Therapeutics-$50.92M-$2.56N/AN/AN/AN/A-30.90%-26.31%N/APSTIPluristem Therapeutics-$49.87M-$1.47N/AN/AN/AN/A-100.63%-55.46%N/ALatest PSTI, JNCE, FENC, EIGR, and GNFT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023FENCFennec Pharmaceuticals$0.02-$0.10-$0.12-$0.10$9.47 million$9.74 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEIGREiger BioPharmaceuticalsN/AN/AN/AN/AN/AFENCFennec PharmaceuticalsN/AN/AN/AN/AN/AGNFTGenfitN/AN/AN/AN/AN/AJNCEJounce TherapeuticsN/AN/AN/AN/AN/APSTIPluristem TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEIGREiger BioPharmaceuticalsN/A3.313.24FENCFennec PharmaceuticalsN/A3.563.27GNFTGenfit0.922.942.94JNCEJounce TherapeuticsN/A8.378.37PSTIPluristem Therapeutics0.578.228.22OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEIGREiger BioPharmaceuticals62.46%FENCFennec Pharmaceuticals55.51%GNFTGenfit2.24%JNCEJounce Therapeutics80.66%PSTIPluristem Therapeutics16.94%Insider OwnershipCompanyInsider OwnershipEIGREiger BioPharmaceuticals4.22%FENCFennec Pharmaceuticals11.25%GNFTGenfit4.20%JNCEJounce Therapeutics6.92%PSTIPluristem Therapeutics5.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableEIGREiger BioPharmaceuticals561.48 million1.42 millionOptionableFENCFennec PharmaceuticalsN/A27.10 million24.05 millionOptionableGNFTGenfit15949.83 million47.74 millionNot OptionableJNCEJounce Therapeutics13752.63 million48.99 millionOptionablePSTIPluristem Therapeutics15332.35 million30.60 millionOptionablePSTI, JNCE, FENC, EIGR, and GNFT HeadlinesSourceHeadlineNBRVF Nabriva Therapeutics plcseekingalpha.com - August 18 at 10:08 PMPluri CEO Issues Shareholder Updatefinance.yahoo.com - July 25 at 8:14 AMPluristem Therapeutics Inc. Changes its Name to "Pluri Inc." Reflecting the Company's Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industriesbenzinga.com - July 25 at 2:34 AMPluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company’s Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industriesfinance.yahoo.com - July 25 at 1:25 AMPluristem (PSTI) Phase III Study Misses Goal, Stock Downfinance.yahoo.com - July 14 at 4:41 PMPluristem Posts Mixed Results From Study Of Muscle Regeneration After Hip Fracture Surgeryfinance.yahoo.com - July 13 at 5:38 PMPluristem's Phase 3 Study Of PLX-PAD To Treat Muscle Injury Does Not Meet Primary Goalmarkets.businessinsider.com - July 13 at 7:28 AMPluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgeryfinance.yahoo.com - July 13 at 7:28 AMPluristem: Fiscal Q3 Earnings Snapshotapnews.com - May 10 at 2:20 PMPluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New Partnershipfinance.yahoo.com - March 28 at 7:49 AMPluristem PLX-R18 shows promise in blood cell recovery in cell transplant patients in trialseekingalpha.com - March 23 at 6:10 PMPluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood Transfusionsfinance.yahoo.com - March 23 at 8:52 AMPluristem Therapeutics, Inc. Common Stock (PSTI)nasdaq.com - March 21 at 8:40 AMPluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venturefinance.yahoo.com - March 8 at 9:53 AMPluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food Platformfinance.yahoo.com - February 24 at 8:48 AMPluristem: Fiscal Q2 Earnings Snapshottimesunion.com - February 8 at 7:12 PMWhat Are The Analysts’ Predictions For Pluristem Therapeutics Inc. (NASDAQ: PSTI)?stocksregister.com - January 18 at 3:31 PMThinking about buying stock in Pluristem Therapeutics, DiDi Global, Robinhood Markets, Bitfarms, or Adamis Pharmaceuticals?marketwatch.com - January 12 at 10:49 PMPluristem Therapeutics Inc. (NASDAQ: PSTI) Is On The Risestocksregister.com - January 11 at 2:09 PMPluristem Therapeutics Inc. (NASDAQ: PSTI) Must Gain 75.17% To Achieve Consensus Price Targetmarketingsentinel.com - January 10 at 6:05 PMIsrael's Tnuva partners with Pluristem to develop cultured cell-based meatmsn.com - January 10 at 1:04 PMBiotech Pluristem, Israel-Based Tnuva Collaborate On Cultured Food Platformfinance.yahoo.com - January 10 at 1:04 PMPluristem Climbs On Collaboration With Tnuva Of Israel For Commercialization Of Alternative Meatnasdaq.com - January 10 at 1:04 PMIs Pluristem Therapeutics (PSTI) Stock a Good Buy?cnafinance.com - January 10 at 1:04 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsEiger BioPharmaceuticalsNASDAQ:EIGREiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.Fennec PharmaceuticalsNASDAQ:FENCFennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.GenfitNASDAQ:GNFTGenfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.Jounce TherapeuticsNASDAQ:JNCEJounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.Pluristem TherapeuticsNASDAQ:PSTIPluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.